PCOS Renamed to PMOS: Why & What This Means

If you have ever been diagnosed with polycystic ovary syndrome, or PCOS, you may have recently come across the news that the condition has a new name. As of May 2026, it is now officially known as Polyendocrine Metabolic Ovarian Syndrome, or PMOS, following a landmark global consensus process published in The Lancet and supported by more than 50 leading patient and professional organisations worldwide, including the Endocrine Society. [1]

Despite the attention this change has received, many patients and clinicians have not yet had it clearly explained to them. If you are wondering what it means for your diagnosis, your treatment, or simply how to understand your condition going forward, you are not alone.

The short answer is that the condition itself has not changed, and neither has your diagnosis. What has changed is that the medical community now has a name that far more accurately reflects what PMOS actually is. This article explains why that matters.

What is PCOS (now PMOS)?

PCOS, now officially renamed PMOS, is one of the most common hormonal conditions affecting women of reproductive age. It is estimated to affect 1 in 8 women, or more than 170 million people worldwide. [1]

The condition is characterised by a combination of hormonal and metabolic disruptions across multiple body systems. Diagnosis is typically made when a person meets at least two of the following three criteria: irregular or absent periods, elevated androgen levels such as testosterone, or polycystic-appearing ovaries on ultrasound or elevated anti-Müllerian hormone (AMH). [2]

Symptoms vary considerably between individuals and can include irregular periods, excess facial or body hair, acne, difficulty conceiving, fatigue, weight changes, and mood disruption. Beyond these more visible features, PMOS is also associated with insulin resistance, an increased long-term risk of type 2 diabetes, cardiovascular disease, sleep apnoea, and metabolic syndrome. The condition also has a meaningful impact on mental wellbeing, with higher rates of anxiety, depression, and reduced quality of life reported compared to the general population. [4]

Why has PCOS been renamed to PMOS?

The renaming reflects a long-overdue recognition that the original name, polycystic ovary syndrome, was inaccurate in ways that caused genuine harm.

The term "polycystic" implies that pathological ovarian cysts are a defining feature of the condition. They are not. What appears on ultrasound are small, immature follicles, not cysts, and research has confirmed there is no actual increase in abnormal ovarian cysts in people with this condition. [1] Large ovarian cysts are not a feature of PMOS. [4] Under the diagnostic criteria, it is entirely possible to receive a diagnosis without any ovarian findings on ultrasound at all. This misnomer contributed to delayed diagnosis, with up to 70% of affected individuals estimated to remain undiagnosed, as well as widespread confusion among patients, clinicians, and policymakers alike. [1]

The new name, Polyendocrine Metabolic Ovarian Syndrome, shifts the focus to what is actually happening. "Polyendocrine" acknowledges that multiple hormonal systems are involved, including insulin, androgens, and neuroendocrine and ovarian hormones, rather than a single organ. "Metabolic" reflects the significant metabolic dimension of the condition, including insulin resistance, which affects the majority of those with PMOS. "Ovarian" retains the ovarian element accurately, without implying cysts. [1]

The name change was the result of 14 years of global collaboration. Professor Helena Teede of Monash University led the process alongside the International Androgen Excess and PCOS Society and Verity, a UK patient charity. The consensus process involved more than 22,000 survey responses from patients and health professionals across all world regions, and multiple international workshops, with agreement on the final name reached in February 2026. [1, 3]

“The renaming of this condition reflects a significant shift in how we understand obesity and related metabolic diseases. It moves the conversation away from outdated assumptions and towards a more accurate recognition of the complex biological, genetic, hormonal, and environmental factors involved. This change signals an evolving scientific understanding that these conditions are chronic diseases requiring evidence-based, compassionate, and personalised care rather than simple lifestyle solutions alone.”

— Dr Saira Bano, GP and Co-Founder, SwiftDoctor

What is the difference between PCOS and PMOS?

The straightforward answer is that PCOS and PMOS are the same condition. This is a renaming, not a reclassification.

The underlying biology has not changed. The diagnostic criteria remain largely the same. The treatments used to manage the condition are unaffected. What is changing is the terminology, and the goal is that more accurate language will lead to better outcomes over time.

The name change is being implemented gradually over a three-year transition period, with full integration planned for the 2028 update of the International Guideline, which is already used in 195 countries. [1] It is also worth noting that clinical coding systems such as ICD-10 and SNOMED will continue to use PCOS for some time, as these systems require their own formal update processes. During this period, both terms will be understood by healthcare professionals, and it will remain important for clinicians, researchers, and patients to recognise that PMOS and PCOS refer to the same underlying condition. [5]

How does the renaming affect diagnosis and treatment?

It does not change either in any immediate or significant way.

Diagnostic criteria, treatment pathways, and clinical guidelines all remain in place. Women will continue to be assessed using the same hormonal, metabolic, and imaging criteria as before. Treatments including hormonal contraception for cycle regulation, metformin for insulin resistance, lifestyle interventions, and fertility support where needed all remain valid and appropriate. [2]

What the shift in terminology may achieve over time is improved recognition and earlier diagnosis. By removing the misleading focus on ovarian cysts, clinicians may feel more confident applying diagnostic criteria to patients who do not present with typical ovarian findings on ultrasound, a group that has historically been underdiagnosed. The change is also expected to strengthen research funding, policy alignment, and public awareness of the full range of features associated with the condition, including its metabolic and cardiovascular dimensions. [1, 6]

What does this mean if you have already been diagnosed with PCOS?

Your diagnosis is completely valid. Nothing about it has been overturned or superseded.

If you were diagnosed with PCOS, you have PMOS. Your management plan, your prescriptions, and any ongoing monitoring you have in place remain appropriate and do not need to be reviewed solely because of the name change.

It is natural to feel unsettled when something as familiar as a condition's name changes, particularly if you have carried a diagnosis for a long time and built your understanding of your health around it. But this change represents progress, not disruption. The renaming process was driven with and for people with the condition, with patients involved at every stage of governance, survey design, and workshop participation. Rachel Morman, Chair of Verity and a lived experience expert on the global steering group, described the new name as one that "leads with hormones and recognises the metabolic dimension of the condition." [3]

If you have questions about your diagnosis or want to understand what the new terminology means in the context of your individual care, your GP or specialist is the best person to speak to.

How SwiftDoctor can support women with PMOS

SwiftDoctor is a doctor-led service that keeps pace with evolving clinical guidance, including changes like the renaming of PCOS to PMOS. Our clinicians understand the full picture of this condition, from its hormonal and metabolic dimensions through to its impact on fertility, mental health, and long-term wellbeing.

Whether you are newly concerned about symptoms, seeking clarity on an existing diagnosis, or looking for ongoing support and monitoring, Our clinicians offer fast, discreet online consultations for women navigating a PMOS diagnosis, with no referral or waiting room required.

Frequently asked questions

What does PMOS stand for? 

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. The three key words reflect the condition's true nature: multiple hormonal systems are involved (polyendocrine), metabolic function is significantly affected, and ovarian dysfunction plays a central role.

Is PCOS the same as PMOS? 

Yes, it is the same condition with a more accurate name. Think of it less as a new diagnosis and more as a correction, one that better reflects what clinicians have understood about the condition for years but that the old name failed to capture.

Why was PCOS renamed to PMOS? 

The name PCOS created widespread confusion by suggesting the condition was primarily about ovarian cysts, which are not actually a defining feature. After 14 years of global collaboration involving over 22,000 patients and clinicians, PMOS was agreed as a name that better captures the hormonal and metabolic complexity of the condition.

Will the renaming improve how PMOS is treated? 

Not immediately in terms of specific treatments, which remain unchanged. However, a more accurate name is expected to improve recognition of the condition's metabolic and hormonal dimensions over time, which may lead to more holistic care, earlier diagnosis, and stronger research funding in areas beyond reproductive health.

I was diagnosed years ago. Do I need to tell my doctor about the name change? 

You do not need to do anything. Your GP or specialist will be aware of the transition and both terms will be understood throughout the changeover period. If you have questions about what the new name means for your care specifically, it is always worth raising at your next appointment.

Disclaimer & Editorial Standards

The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.

The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.

Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.

Sources

1. Teede, H.J. et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext

2. Teede, H.J. et al. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology, 189, G43–G64. https://doi.org/10.1093/ejendo/lvad107

3. Endocrine Society (2026). Polyendocrine Metabolic Ovarian Syndrome: new name to improve diagnosis and care of condition affecting 170 million women worldwide. Press release, 12 May 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change

4. Mayo Clinic (2026). Polyendocrine metabolic ovarian syndrome (PMOS): symptoms and causes. https://www.mayoclinic.org/diseases-conditions/pcos/symptoms-causes/syc-20353439

5. BMJ (2026). PCOS name change to PMOS must be managed to avoid confusing patients, says expert. BMJ, 393, s955. https://doi.org/10.1136/bmj.s955

6. BMJ (2026). Improving awareness and care in polyendocrine metabolic ovarian syndrome (formerly polycystic ovary syndrome). BMJ, 393, s893. https://doi.org/10.1136/bmj.s893